Contribution of midgut bacteria to blood digestion and egg production in aedes aegypti (diptera: culicidae) (L.)

<p>Abstract</p> <p>Background</p> <p>The insect gut harbors a variety of microorganisms that probably exceed the number of cells in insects themselves. These microorganisms can live and multiply in the insect, contributing to digestion, nutrition, and development of their host.</p> <p>Recent studies have shown that midgut bacteria appear to strengthen the mosquito's immune system and indirectly enhance protection from invading pathogens. Nevertheless, the physiological significance of these bacteria for mosquitoes has not been established to date. In this study, oral administration of antibiotics was employed in order to examine the contribution of gut bacteria to blood digestion and fecundity in <it>Aedes aegypti</it>.</p> <p>Results</p> <p>The antibiotics carbenicillin, tetracycline, spectinomycin, gentamycin and kanamycin, were individually offered to female mosquitoes. Treatment of female mosquitoes with antibiotics affected the lysis of red blood cells (RBCs), retarded the digestion of blood proteins and reduced egg production. In addition, antibiotics did not affect the survival of mosquitoes. Mosquito fertility was restored in the second gonotrophic cycle after suspension of the antibiotic treatment, showing that the negative effects of antibiotics in blood digestion and egg production in the first gonotrophic cycle were reversible.</p> <p>Conclusions</p> <p>The reduction of bacteria affected RBC lysis, subsequently retarded protein digestion, deprived mosquito from essential nutrients and, finally, oocyte maturation was affected, resulting in the production of fewer viable eggs. These results indicate that <it>Ae. aegypti </it>and its midgut bacteria work in synergism to digest a blood meal.</p> <p>Our findings open new possibilities to investigate <it>Ae. aegypti</it>-associated bacteria as targets for mosquito control strategies.</p

Antimicrobial activity of silver nanoparticles synthesized by the fungus Curvularia inaequalis

Silver nanoparticles have been widely reported in literature due to their vast industrial application in different areas. In this work, we explored a simple procedure for the biosynthesis of silver nanoparticles at room temperature from the action of Curvularia inaequalis as reduction agent. The degree of aggregation and size of biosynthesized particles were optimized from a factorial design involving combined variation of three different parameters of preparation. The resulting colloidal dispersion of silver nanoparticles presented strong antimicrobial activity against Escherichia coli and Klebsiella pneumoniae in an indication that C. inaequalis represents a new potential candidate for alternative biosynthesis of silver nanoparticles with antimicrobial activity.Keywords: Antimicrobial activity, fungi, silver nanoparticlesAfrican Journal of Biotechnology Vol. 12(20), pp. 2917-292

Platform for Plasmodium vivax vaccine discovery and development

Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development